See more : Koninklijke KPN N.V. (KKPNY) Income Statement Analysis – Financial Results
Complete financial analysis of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Contineum Therapeutics, Inc. Class A Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Almunda Professionals N.V. (AMUND.AS) Income Statement Analysis – Financial Results
- Flekkefjord Sparebank (FFSB.OL) Income Statement Analysis – Financial Results
- Worth Investment & Trading Company Limited (WORTH.BO) Income Statement Analysis – Financial Results
- Strong H Machinery Technology (Cayman) Incorporation (4560.TW) Income Statement Analysis – Financial Results
- Korean Reinsurance Company (003690.KS) Income Statement Analysis – Financial Results
Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 50.00M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 329.00K | 0.00 |
| Gross Profit | 50.00M | -329.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% |
| Research & Development | 27.60M | 16.89M | 22.36M |
| General & Administrative | 6.32M | 5.83M | 6.29M |
| Selling & Marketing | 0.00 | -329.00K | 0.00 |
| SG&A | 6.32M | 5.50M | 6.29M |
| Other Expenses | 0.00 | -92.00K | -91.00K |
| Operating Expenses | 33.92M | 22.39M | 28.65M |
| Cost & Expenses | 33.92M | 22.72M | 28.65M |
| Interest Income | 4.61M | 761.00K | 77.00K |
| Interest Expense | 208.00K | 388.00K | 332.00K |
| Depreciation & Amortization | 195.00K | 329.00K | 325.00K |
| EBITDA | 23.57M | -23.54M | -28.34M |
| EBITDA Ratio | 47.15% | 0.00% | 0.00% |
| Operating Income | 16.08M | -22.72M | -28.65M |
| Operating Income Ratio | 32.15% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.09M | -1.53M | -354.00K |
| Income Before Tax | 23.17M | -24.25M | -29.00M |
| Income Before Tax Ratio | 46.34% | 0.00% | 0.00% |
| Income Tax Expense | 450.00K | 0.00 | 241.00K |
| Net Income | 22.72M | -24.25M | -29.00M |
| Net Income Ratio | 45.44% | 0.00% | 0.00% |
| EPS | 1.36 | -0.97 | -1.74 |
| EPS Diluted | 1.28 | -0.97 | -1.63 |
| Weighted Avg Shares Out | 16.67M | 25.13M | 16.67M |
| Weighted Avg Shares Out (Dil) | 17.76M | 25.13M | 17.76M |
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience,...
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience,...
Contineum Therapeutics to Attend Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience,...
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I)...
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I)...
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Contineum Therapeutics, Inc. PIPE-791 is being developed for the treatment of neuroinflammatory disorders like idiopathic pulmonary fibrosis and Progressive Multiple Sclerosis. The global idiopathic pulmonary fibrosis market size is projected to reach $6.45 billion by 2031. The global multiple sclerosis...
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I)...
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I)...
Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of NI&I indications, today reported financial...
U.S. IPO Weekly Recap: April IPO Market Gets A Boost From Large Launches And New Filings
Three IPOs priced in the first week of April, led by a sizable biotech. Two sizable listings are currently scheduled for the week ahead, although smaller issuers may join the calendar throughout the week.
Source: https://incomestatements.info
Category: Stock Reports